1. Home
  2. STN vs CYTK Comparison

STN vs CYTK Comparison

Compare STN & CYTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Stantec Inc

STN

Stantec Inc

HOLD

Current Price

$76.37

Market Cap

10.3B

ML Signal

HOLD

Logo Cytokinetics Incorporated

CYTK

Cytokinetics Incorporated

HOLD

Current Price

$73.69

Market Cap

10.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
STN
CYTK
Founded
1954
1997
Country
Canada
United States
Employees
N/A
N/A
Industry
Military/Government/Technical
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
10.3B
10.4B
IPO Year
2005
2004

Fundamental Metrics

Financial Performance
Metric
STN
CYTK
Price
$76.37
$73.69
Analyst Decision
Buy
Strong Buy
Analyst Count
1
19
Target Price
$175.00
$89.26
AVG Volume (30 Days)
320.6K
3.1M
Earning Date
05-13-2026
05-05-2026
Dividend Yield
0.74%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$13,368,000.00
Revenue This Year
$11.06
$7.37
Revenue Next Year
$6.61
$310.19
P/E Ratio
$28.96
N/A
Revenue Growth
N/A
N/A
52 Week Low
$72.46
$30.81
52 Week High
$114.52
$80.20

Technical Indicators

Market Signals
Indicator
STN
CYTK
Relative Strength Index (RSI) 36.11 51.08
Support Level $72.46 $73.00
Resistance Level $95.02 $79.66
Average True Range (ATR) 3.16 2.57
MACD -0.10 -0.53
Stochastic Oscillator 28.91 13.81

Price Performance

Historical Comparison
STN
CYTK

About STN Stantec Inc

Stantec Inc is a sustainable engineering, architecture, and environmental consulting company. It offers services through the following business operating units; Environmental Services, Infrastructure, Water, Buildings, and Energy & Resources. Maximum revenue is derived from its Infrastructure business unit, which is engaged in evaluating, planning, and designing infrastructure solutions for transportation, community development, and urban spaces. The company's reportable segments are the United States, which derives maximum revenue, Canada, and Global. These segments provide consulting in engineering, architecture, interior design, landscape architecture, surveying, environmental sciences, project management, and project economics services in the area of infrastructure and facilities.

About CYTK Cytokinetics Incorporated

Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The company's product, named as MYQORZO, is an allosteric and reversible inhibitor of cardiac myosin motor activity. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.

Share on Social Networks: